Risks and Benefits of Gene Therapy for Immunodeficiency: a Reality Check
Open Access
- 8 November 2002
- journal article
- editorial
- Published by Springer Nature in Gene Therapy
- Vol. 9 (23) , 1561-1562
- https://doi.org/10.1038/sj.gt.3301924
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Stable nonviral genetic correction of inherited human skin diseaseNature Medicine, 2002
- HIV-1 Integration in the Human Genome Favors Active Genes and Local HotspotsCell, 2002
- Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene TherapyNew England Journal of Medicine, 2002
- Preferential integration of human immunodeficiency virus type 1 into genes, cytogenetic R bands and GC‐rich DNA regions: insight from the human genome sequenceFEBS Letters, 2002
- Directed evolution of a recombinase for improved genomic integration at a native human sequenceNucleic Acids Research, 2001
- Initial sequencing and analysis of the human genomeNature, 2001
- Relationship between Retroviral DNA Integration and Gene ExpressionJournal of Virology, 2000
- Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 DiseaseScience, 2000
- Transcriptionally active genome regions are preferred targets for retrovirus integrationJournal of Virology, 1990